Results 121 to 130 of about 10,751 (182)

Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review. [PDF]

Cancers (Basel)
Saalfeld FC, Overbeck TR.
europepmc   +1 more source

Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan. [PDF]

Future Oncol
Kawakami H, Tanizawa Y, Shimizu T.
europepmc   +1 more source

Dynamic HER2 reassessment and precision sequencing after trastuzumab in HER2-positive advanced gastric cancer. [PDF]

ESMO Gastrointest Oncol
Ooki A, Shimozaki K, Yamaguchi K.
europepmc   +1 more source

Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel-Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan. [PDF]

Cancers (Basel)
Nagasaka T, Kono Y, Kito Y, Ando T, Negoro Y, Abe T, Kuramochi H, Boku S, Mannami T, Nasu J, Inoue M, Nakamura M, Okita Y, Shindo Y, Yamada T, Maeda T, Shinohara Y, Tanioka H.   +17 more
europepmc   +1 more source

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors. [PDF]

Cancer Sci
Matsumoto K, Naito Y, Shiroyama T.
europepmc   +1 more source

Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review. [PDF]

J Cardiothorac Surg
Tsai YH, Weng YS, Huang TW.
europepmc   +1 more source

When Binding Is Not Blockade: Interpreting IgG4⁺ T Cells After PD-1 Therapy. [PDF]

Cancer Sci
Sun M, Zang D, Chen J.
europepmc   +1 more source

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics. [PDF]

Front Pharmacol
Li J, Cheng Y, Yang Y.
europepmc   +1 more source

Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture. [PDF]

Bioprocess Biosyst Eng
Cagatay E, Gungor Y, Ozturk SS, Kayali HA.   +3 more
europepmc   +1 more source